MedTrace Logo

Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001

NCT00775073 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2012-04-30

No results posted yet for this study

Summary

This is a prospective open label clinical trial in patients with advanced or metastatic liver cancer to assess the clinical and biological activity of RAD001 (Everolimus) in conjunction with Bevazicumab (Avastin). Approximately 36 patients will be enrolled.

Conditions

Interventions

DRUG

Everolimus, Bevacizumab

Everolimus 5 mg tablet per day orally. Bevazicumab 5 mg per kg intravenous every 2 weeks.

Sponsors & Collaborators

  • Crolll Gmbh

    collaborator OTHER

  • Estimate, GmbH

    collaborator INDUSTRY

  • Janssen Diagnostics, LLC

    collaborator INDUSTRY

  • Gerhard Treiber

    lead INDIV

Principal Investigators

  • Gerhard Treiber, PD Dr. · Zollernalbklinikum Balingen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-01-31
Completion
2012-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00775073 on ClinicalTrials.gov